FDA Reverses Course, Allows Sarepta to Resume Duchenne Gene Therapy Shipments on July 29, 2025 Elevidys gene therapy Muscular Dystrophy, Duchenne Pauses Resumption Safety shipment United States Food and Drug Administration +